KRAS and colorectal carcinoma: These patients had an overall median PFS of 4 months and a median TTCM of 5.5 months, which is in line with the PFS of 4.3 months reported for patients with wild-type KRAS metastatic CRC and frail older patients treated with panitumumab as a single agent in a study by the Spanish Digestive Oncology Collaborative Group (Sastre et al., 2015).